Improvement of Treatment Outcomes for Metastatic Pancreatic Cancer: A Real-world Data Analysis.
In Vivo
; 33(1): 271-276, 2019.
Article
en En
| MEDLINE
| ID: mdl-30587635
ABSTRACT
BACKGROUND/AIM:
FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, oxaliplatin) and gemcitabine plus nab-paclitaxel therapy have recently been introduced for the treatment of metastatic pancreatic cancer. Herein, overall treatment outcomes of metastatic pancreatic cancer after introduction of FOLFIRINOX and gemcitabine plus nab-paclitaxel therapy were evaluated, in daily practice. PATIENTS ANDMETHODS:
Metastatic pancreatic cancer patients (n=321) who started systemic chemotherapy between January 2011 and December 2016 were included and were divided into two groups group A (2011-2013) and group B (2014-2016). Treatment outcomes were evaluated retrospectively.RESULTS:
Patient characteristics were similar between the two groups except for the rates of distant lymph node metastasis and peritoneal metastasis. The preferred regimens in groups A and B were gemcitabine monotherapy and gemcitabine plus nab-paclitaxel therapy, respectively. The response rates, median progression-free survival, and median overall survival of groups A and B were 7.8% and 28.4% (p<0.01), 3.1 months and 5.4 months (p<0.01), and 6.7 months and 10.2 months (p<0.01), respectively.CONCLUSION:
Overall treatment outcomes for metastatic pancreatic cancer were significantly improved after introduction of FOLFIRINOX and gemcitabine plus nab-paclitaxel combination therapy in daily practice.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Compuestos Organometálicos
/
Neoplasias Pancreáticas
/
Leucovorina
/
Paclitaxel
/
Desoxicitidina
/
Albúminas
/
Fluorouracilo
Límite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Año:
2019
Tipo del documento:
Article